Oncoinvent to present three abstracts at EANM and ESMO 2026

Oslo, Norway – 30 September 2026 – Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin^®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that three abstracts from its Radspherin^® program have been accepted for presentation at the European Association of Nuclear Medicine (EANM) Annual Congress 2026 in Vienna, Austria (17-21 October) and the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (23-27 October).

The accepted abstracts highlight key areas of the Radspherin^® program, including Radium-224 production technology, radiation dosimetry and the ongoing Phase 2 clinical evaluation of Radspherin^® in ovarian cancer. Two abstracts will be presented at EANM and one at ESMO.

Øystein Soug, Chief Executive Officer of Oncoinvent, said: “We are pleased to have three abstracts accepted for presentation at EANM and ESMO 2026. Together, they highlight research across the Radspherin^® program, from Radium-224 production and radiation dosimetry to ongoing clinical development in ovarian cancer. We look forward to sharing our work with the scientific community at both meetings.”

EANM 2026:

ESMO 2026:

***

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com

Optimum Strategic Communications
Zoe Bolt, Elena Bates, Katherine Bliss
+44 (0) 203 882 9621
oncoinvent@optimumcomms.com

About Oncoinvent

Oncoinvent is developing Radspherin^®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin^® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2H2026 (safety) and 1H2027 (early efficacy). With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).

About Radspherin^®

Radspherin^® is an investigational radiopharmaceutical designed for the local treatment of cancer that has spread to body cavities. It consists of billions of calcium carbonate microparticles containing the radioactive material radium-224. The mode of action is the decay of radium-224 emitting alpha-particles, a highly potent form of ionizing radiation. Radspherin^® is being investigated in clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal cancer and it is administered intraperitoneally following surgical resection with removal of all macroscopic disease.